… quarter. The momentum in Q1 is continuing into Q2, … of revenue, Tubi achieved 27% revenue growth in the first quarter, driven … businesses, to be hitting profitability earlier than expected will … advertising, very strong in pharma in the quarter, financial …

… October 30, 2025 Phathom Pharmaceuticals, Inc. beats earnings … of building successful profitable pharmaceutical businesses of significant scale … 50% since Q1 while growing revenues ahead of … be operating profit — in operating profit position next …

… of consistent improvement. First-Quarter 2026 Highlights • Revenue: $3,197, … 2,666,279 in Q1 2025. • Gross Profit: $761,316, up … for government, pharmaceutical and commercial contracts. … Performance Summary Total Revenue: 3 Months Ended Aug …

Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis  Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0% Income from operations increased 15%; non-GAAP income from operations up 19% Diluted earnings per share …

… profit $667 million $530 million 26 %   First quarter revenue for the Pharmaceutical … first quarter, primarily driven by growth from existing customers. Other3 Q1 FY26 Q1 FY25 Y/Y Revenue … Profit margin: segment profit divided by segment revenue. Non- …

… October 29, 2025 Vanda Pharmaceuticals Inc. misses on earnings … financial objectives in 2025. Total revenues from Fanapt, HETLIOZ, and … consumer campaign launched in the first quarter, which continued to drive … we saw 14% growth Q1 to Q2 and 11% growth …

… first quarter for fiscal 2026, beating both earnings and revenue … or accounting trick. Pharmaceutical and Specialty Solutions, … Operating earnings growth outpaced revenue growth. Non-GAAP … to specialty pharmaceutical services and should provide …

… Nile Co. for Pharmaceuticals and Chemical Industries (NIPH) turned profitable, with EGP … 106.525 million in the first quarter (Q1) of … EGP 11.738 million in Q1 FY2024/25. Net … 125.727 million in net profits in FY 2024/2025 …

By the numbers   Q3 sales: $1.55 billion 14.7% increase year over year   TAVR sales: $1.15 billion 12.4% increase year over year   TMTT sales: $145.2 million 59.3% increase year over year Edwards Lifesciences CFO Scott Ullem will step down by mid-2026, the …

… First-quarter revenue increased 22% year-over-year to $64 billion The Pharmaceutical … Medical Products and Distribution revenue rose 2% Net income … .88 per share in Q1 2025 Operating earnings increased … $668 million in the first quarter; adj. operating earnings …